Nama's AI scorecard currently rates Maze Therapeutics Sell (2.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does MAZE report earnings?

Maze Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.75.

What is the MAZE price target?

The median analyst price target from 13 analysts is $55.00, with a range of $46.00 – $110.00.

Is MAZE Shariah compliant?

Nama's AAOIFI-style screen reads Maze Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Maze Therapeutics (MAZE)

Healthcare · Biotechnology · NASDAQ

Maze Therapeutics (MAZE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.90B and a free-cash-flow yield of -7.7%. Over the most recent reported fiscal year, revenue declined 100.0% and free cash flow per share fell 253.5%. Nama's AI scorecard rates it Sell, 2.4 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 2.4/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -11.4% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-36.3%

How far the last close sits under the highest price of the past five years.

Market cap	$1.90B
Trailing P/E	—
Price / book	4.2
Price / sales	95.0
FCF yield	-7.7%
Dividend yield	—
Gross margin	100.0%
Operating margin	-728.1%
Net margin	0.0%
Revenue growth (YoY)	-100.0%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	-253.5%
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

MAZE earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.75). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.76	-$0.70	-8.6%	$0
Q4 2025	Mar 25, 2026	-$0.65	-$0.69	+5.8%	$0
Q3 2025	Nov 6, 2025	-$0.66	-$0.69	+4.3%	$0
Q2 2025	Aug 12, 2025	-$0.77	-$1.15	+33.0%	$0

MAZE analyst price target

Median target $55.00 from 13 analysts, ranging $46.00 – $110.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live MAZE data on Nama Insights →

MAZE FAQ

Is MAZE a buy?: Nama's AI scorecard currently rates Maze Therapeutics Sell (2.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MAZE report earnings?: Maze Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.75.
What is the MAZE price target?: The median analyst price target from 13 analysts is $55.00, with a range of $46.00 – $110.00.
Is MAZE Shariah compliant?: Nama's AAOIFI-style screen reads Maze Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.